CALDRE is a University of Bern spin-out developing ClagalsiR, a GalNAc-siRNA for cholestatic and fibrotic liver diseases affecting more than 370,000 patients in major markets. Many lack effective therapy and progress to transplantation. ClagalsiR targets claudin-3, a unique mechanism that boosts bicarbonate-rich bile, reduces toxic bile acids and protects liver tissue. Preclinical data show clear reductions in bile acid load and injury. Backed by Swiss innovation programs, CALDRE is expanding a pipeline in tight-junction modulation and advancing toward IND-enabling studies.